Making Early Decisions In Psychiatric Drug Development: The Role of Pharmacodynamic Biomarkers

Early psychiatric drug development is often challenged by high attrition rates, driven by the complexity of CNS disorders and the limitations of traditional symptom-based endpoints. Quantitative pharmacodynamic (PD) measures offer a more objective way to evaluate whether investigational therapies are engaging their intended targets and producing meaningful biological effects in humans.

By combining biomarkers such as EEG, neuroimaging, cognitive assessments, eye-tracking, and digital measures with pharmacokinetic data, researchers can establish clear exposure-response relationships and gain earlier insight into a compound's therapeutic potential. These approaches help support dose selection, reduce uncertainty, and strengthen go/no-go decisions before significant resources are committed to later-stage trials.

Quantitative PD measures also enable more precise patient stratification, improve translational confidence between preclinical and clinical findings, and provide objective evidence less vulnerable to placebo effects. As psychiatric drug development moves toward mechanism-based and precision medicine approaches, integrated biomarker strategies are becoming an essential tool for improving decision-making and development success.